drugset / Trial / NCT01014858
Multi-centre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated With Parkinson's Disease
Phase 3
Terminated
64 enrolled
Newcastle-upon-Tyne Hospitals NHS Trust
Bangor University · collabKing's College London · collabLancashire Care NHS Foundation Trust · collabLondon School of Economics and Political Science · collabNewcastle University · collabUniversity College, London · collabUniversity of Birmingham · collabUniversity of Cambridge · collabUniversity of Manchester · collabUniversity of Newcastle Upon-Tyne · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To demonstrate the superiority of donepezil over placebo in improving cognitive function, neuropsychiatric burden and functional ability in people with Parkinson's disease and mild dementia after 24 months of treatment. To demonstrate the superiority of donepezil over placebo in improving patient and carer quality of life and to establish the cost-effectiveness of donepezil. To determine the instrument most suitable for evaluating change in cognition in people with Parkinson's disease and mild dementia.
Timeline
- Start
- 2013-01
- Primary completion
- 2014-09
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donepezil | Small molecule | 10 mg | — |